The response-guided ATG treatment provides a survival benefit and KPS recovery for patients with steroid refractory acute GVHD: The Nagasaki Transplant Group Experience.

[1]  J. Nakashima,et al.  Treatment with mogamulizumab or lenalidomide for relapsed adult T‐cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation: The Nagasaki transplant group experience , 2019, Hematological oncology.

[2]  E. Shpall,et al.  A Phase 3 randomized study of Remestemcel-L versus placebo added to second line therapy in patients with steroid refractory acute graft versus host disease. , 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[3]  S. Grupp,et al.  The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease. , 2019, Blood advances.

[4]  Y. Kanda,et al.  Resolved versus Active Chronic Graft-versus-Host Disease: Impact on Post-Transplantation Quality of Life. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[5]  T. Luft,et al.  Shaping of CD56bri Natural Killer Cells in Patients With Steroid-Refractory/Resistant Acute Graft-vs.-Host Disease via Extracorporeal Photopheresis , 2019, Front. Immunol..

[6]  N. Kröger,et al.  MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD. , 2018, Blood.

[7]  Y. Kanda,et al.  Quality of Life after Allogeneic Hematopoietic Cell Transplantation According to Affected Organ and Severity of Chronic Graft-versus-Host Disease. , 2017, Biology of Blood and Marrow Transplantation.

[8]  H. Ogawa,et al.  Low-dose thymoglobulin as second-line treatment for steroid-resistant acute GvHD: an analysis of the JSHCT , 2017, Bone Marrow Transplantation.

[9]  N. Kröger,et al.  An early-biomarker algorithm predicts lethal graft-versus-host disease and survival. , 2017, JCI insight.

[10]  H. Greinix,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease , 2015 .

[11]  M. Hino,et al.  Response-guided therapy for steroid-refractory acute GVHD starting with very-low-dose antithymocyte globulin. , 2015, Experimental hematology.

[12]  A. Gennery,et al.  Extracorporeal photopheresis for treatment of adults and children with acute GVHD: UK consensus statement and review of published literature , 2014, Bone Marrow Transplantation.

[13]  S. Honda,et al.  Distinct clinical features of infectious complications in adult T cell leukemia/lymphoma patients after allogeneic hematopoietic stem cell transplantation: a retrospective analysis in the Nagasaki transplant group. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[14]  Y. Kanda,et al.  Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.

[15]  J. Wingard,et al.  First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[16]  R. Porcher,et al.  Steroid-refractory acute GVHD: lack of long-term improved survival using new generation anticytokine treatment. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[17]  B. Storer,et al.  Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. , 2011, Blood.

[18]  B. Kurland,et al.  Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. , 2011, Blood.

[19]  M. Gramatzki,et al.  Therapy of steroid-refractory acute GVHD with CD52 antibody alemtuzumab is effective , 2011, Bone Marrow Transplantation.

[20]  R. Storb,et al.  Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. , 2009, Blood.

[21]  B. Sandmaier,et al.  Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[22]  R. Soiffer,et al.  Quality of life associated with acute and chronic graft-versus-host disease , 2006, Bone Marrow Transplantation.

[23]  H. Greinix,et al.  The effect of intensified extracorporeal photochemotherapy on long-term survival in patients with severe acute graft-versus-host disease. , 2006, Haematologica.

[24]  M. Zahurak,et al.  Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[25]  J. Wagner,et al.  Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[26]  R. Vij,et al.  Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin , 2001, Bone Marrow Transplantation.

[27]  S. Mineishi,et al.  Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: a single-center experience in Japan , 2001, Bone Marrow Transplantation.

[28]  J Crowley,et al.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.

[29]  G. Dini,et al.  Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation. , 1998, Blood.

[30]  A. Gratwohl,et al.  A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow Transplantation (EBMT) , 1997, Bone Marrow Transplantation.

[31]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[32]  K. Sullivan,et al.  A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. , 1990, Blood.

[33]  L. VázquezSell,et al.  Graft-versus-host disease. , 1991, The New England journal of medicine.